A phase I/II proof-of-concept study evaluating intramuscular injection of AT-982 in adult subjects with Pompe disease.

Trial Profile

A phase I/II proof-of-concept study evaluating intramuscular injection of AT-982 in adult subjects with Pompe disease.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs AT 982 (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2018 According to an Audentes Therapeutics media release, the company plans to file an IND for AT982 in the second quarter of 2018 and plans to initiate a Phase 1/2 clinical study in the fourth quarter of 2018.
    • 19 May 2017 New trial record
    • 11 May 2017 According to an Audentes Therapeutics media release, preliminary data from this study is anticipated in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top